The effect of lowering uric acid is significantly better than febuxostat!

Text | pick up shells

On July 1, South Korea’s LG Chemical Company announced the top-line results of a phase II study of a new non-purine xanthine oxidase (XO) inhibitor LC350189, which aims to evaluate the safety of LC350189 in the chronic management of hyperuricemia in patients with gout Sex and efficacy

LC350189 is a new type of xanthine oxidase inhibitor, which reduces the production of uric acid, the final product of purine metabolism by inhibiting the activity of xanthine oxidase

According to ACR criteria, patients with baseline sUA levels ≥8 mg/dL and ≤12 mg/dL received LC350189 (50, 100, and 200 mg) or placebo orally for 3 months

The results of the study showed that at the third month, the proportions of subjects in the LC350189 different dose groups reaching sUA<5mg/dL were 47% (16/34, 50mg), 45% (17/38, 100mg), 62% (23/ 37,200 mg), the febuxostat group was 23% (3/13), and the placebo group was only 3% (1/34)

Compared with the placebo group in terms of safety, LC350189 is well tolerated in patients with gout at all dose levels

Original title: The effect of lowering uric acid is significantly better than febuxostat! New XO Inhibitor Phase II Data Announcement